TOP TEN perturbations for Q496J9 (Homo sapiens)

Organism: Homo sapiens
Gene: Q496J9
Selected probe(set): 216086_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q496J9 (216086_at) across 5610 perturbations tested by GENEVESTIGATOR:

HIV-associated neurocognitive disorder study 9 (HIVE) / HIV-associated dementia study 1

Relative Expression (log2-ratio):-4.7014
Number of Samples:5 / 7
Experimental HIV-associated neurocognitive disorder study 9 (HIVE)
Postmortem cerebral white matter tissue from HIV-1-infected patients with substantial HIV-associated neurocognitive impairment (HAND). Patients had no encephalitis (HIVE) or other neuropathological defect.
Control HIV-associated dementia study 1
Postmortem basal ganglia tissue from HIV-1-infected patients with substantial HIV-associated neurocognitive impairment (HAND). Patients had no encephalitis (HIVE) or other neuropathological defect.

Parkinson's disease study 6 / normal pars reticulata tissue

Relative Expression (log2-ratio):-4.571288
Number of Samples:3 / 4
Experimental Parkinson's disease study 6
Pars reticulata tissue from patients with Parkinson's disease.
Control normal pars reticulata tissue
Normal pars reticulata tissue.

HIV-associated neurocognitive disorder study 7 (normal) / HIV-associated neurocognitive disorder study 6 (normal)

Relative Expression (log2-ratio):3.7553596
Number of Samples:2 / 2
Experimental HIV-associated neurocognitive disorder study 7 (normal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients received antiretroviral therapy (ART).
Control HIV-associated neurocognitive disorder study 6 (normal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients did not receive any antiretroviral therapy (ART).

null cell adenoma study 1 / gonadotroph adenoma study 1

Relative Expression (log2-ratio):-3.6002283
Number of Samples:2 / 7
Experimental null cell adenoma study 1
Null cell adenoma biopsy samples recovered during transsphenoidal surgery. The tumors were defined by gonadotropic staining for FSH, LH, or alpha subunit in less than 5-10% of cells. Samples were scanned between 04/6/2004 - 15/4/2005.
Control gonadotroph adenoma study 1
Gonadotroph adenoma biopsy samples recovered during transsphenoidal surgery. The tumors were defined as demonstrating positive immunostaining for FSH, LH, or alpha subunit in greater than 5-10% of cells. Samples were scanned between 04/6/2004 - 15/4/2005.

zalypsis study 1 / untreated MM1S cell sample

Relative Expression (log2-ratio):-3.5363255
Number of Samples:2 / 2
Experimental zalypsis study 1
MM1S multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated MM1S cell sample
MM1S multiple myeloma cells untreated.

small cell lung cancer study 4 (XCL from PDX) / small cell lung cancer study 4 (XCL from CDX)

Relative Expression (log2-ratio):3.4398184
Number of Samples:3 / 11
Experimental small cell lung cancer study 4 (XCL from PDX)
Xenograft-derived cell lines (XCL) established from a small cell lung carcinoma (SCLC) patient derived xenografts (PDX). The discarded tissue from three chemo-naive patients (LX22; LX33 and LX35) was obtained during bronchoscopy and used to generate a xenograft. Aseptically resuspended tumour cells were injected s.c. in the flanks of nonobese diabetic/severe combined immunodeficient mice. The mice were sacrificed when the P0 tumors reached 1cm in diameter. Obtained cells were used for conventional cell culture cultivation.
Control small cell lung cancer study 4 (XCL from CDX)
Xenograft-derived cell lines (XCL) established from a small cell lung carcinoma (SCLC) publicly available cell lines derived xenografts (CDX derived cell lines). Xenografts were grown in the flanks of a nude mice. Obtained cells were cultivated under conventional tissue culture conditions.

TC-71 / TC-32

Relative Expression (log2-ratio):-3.2961473
Number of Samples:6 / 6
Experimental TC-71
Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code:
Control TC-32
Human primary cancer cell line derived from the unspecified origin of a patient with Ewing’s sarcoma. Synonyms:TC32 Cellosaurus code:

HIV-associated neurocognitive disorder study 7 (normal) / normal genu sample

Relative Expression (log2-ratio):3.290907
Number of Samples:2 / 8
Experimental HIV-associated neurocognitive disorder study 7 (normal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients received antiretroviral therapy (ART).
Control normal genu sample
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from healthy subjects.

Parkinson's disease study 5 / normal pars compacta tissue

Relative Expression (log2-ratio):-3.2763186
Number of Samples:2 / 5
Experimental Parkinson's disease study 5
Pars compacta tissue from patients with Parkinson's disease.
Control normal pars compacta tissue
Normal pars compacta tissue.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):-3.2664843
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---